Why the study?
The regulatory mechanisms governing the cardiac inflammatory response to endotoxin, which causes severe cardiac dysfunction, are not fully understood.
Does whole-body or endothelium-specific knockout of coxsackie and adenovirus receptor (CXADR) alter cardiac dysfunction, myocardial inflammation, and survival in an experimental mouse model of endotoxin-induced failing heart?
Does whole-body or endothelium-specific knockout of coxsackie and adenovirus receptor (CXADR) alter cardiac dysfunction, myocardial inflammation, and survival in an experimental mouse model of endotoxin-induced failing heart?
This preclinical study demonstrates that coxsackie and adenovirus receptor (CXADR) plays a dual cell-type-dependent role in endotoxin-induced cardiac dysfunction—acting as a pro-inflammatory mediator in endothelial cells and an anti-inflammatory protector globally via differential regulation of the MKK3/6-p38 and IL-17A pathways.
Answers are grounded in this paper and cite their sources.
Does not support clinical CXADR modulation yet; leaves open cell-specific targeting in inflammatory cardiac dysfunction.
The regulatory mechanisms for inflammatory response in the heart to endotoxin, which causes severe cardiac dysfunction, are not fully understood. We hypothesized the involvement of coxsackie and adenovirus receptor (CXADR), which can promote tissue inflammation by potentiating cell-cell adhesion, independent of viral infection, and examined the role of CXADR in endotoxin-induced cardiac dysfunction and its mechanism using an experimental mouse model. Conditional whole-body and endothelium-specific CXADR knockout (W-KO and E -KO, respectively) mice were generated using the Cre-loxP system and administered lipopolysaccharide (LPS) or vehicle alone, like wild-type (WT) mice. Cardiac CXADR increased 12 h after LPS challenge in WT mice, along with improved cardiac dysfunction and reduced cardiac expression of interleukin (IL)-6 and IL-1β. Moreover, W-KO in adult mice worsened cardiac dysfunction and increased expression of these cytokines. Meanwhile, E -KO exhibited the opposite effects, concomitantly reducing myocardial inflammation. Bulk RNA sequencing analysis identified an enriched IL-17 A signaling pathway capable of inducing IL-6 and IL-1β expression in the heart 12 h after LPS challenge. In this heart, E -KO attenuated phosphorylation of p38 but not of upstream mitogen-activated protein kinase kinase (MKK)3/6. Conversely, W-KO augmented phosphorylation of p38, MKK3/6, and NF-κB/p65, which are key drivers of the IL-17 A signaling. Our study is the first to demonstrate that increased CXADR expression plays a dual role as both a pro-inflammatory mediator and an anti-inflammatory protector in endotoxin-induced cardiac dysfunction, possibly by positively or negatively regulating p38 activation depending on its cellular origin. Targeted manipulation of CXADR expression may provide clinical benefits. • Expression of CXADR is increased in endotoxin-stressed heart. • IL-17A-mediated inflammatory response underlies endotoxin-induced failing heart. • CXADR plays dual pro- and anti-inflammatory roles in the heart. • CXADR diversely regulates the MKK3/6-p38 pathway in the heart. • Targeted manipulation of CXADR expression may provide clinical benefits.
No takes yet. Share an insight, caveat, or question.
Matsumura et al. (2025) studied Endotoxin-induced cardiac dysfunction. Endothelium-specific CXADR knockout vs. Wild-type/control mice was evaluated on 72-hour survival after 20 mg/kg LPS challenge (p=0.0193).
Synapse has enriched 10 related papers. Consider them for comparative context: